Invitae Feb 18, 2022 Invitae Launches Study to Generate Real-World Data on Personalized MRD Test Across Tumor Types Premium Feb 16, 2022 Invitae Garners CE-IVD Mark for Two Comprehensive Genomic Profiling Tests Jan 12, 2022 Invitae Launches Ciitizen Genome Information Management Platform at JPM Nov 9, 2021 Invitae Unveils Plans to Expand Cancer Testing Portfolio Premium Oct 18, 2021 Outcomes4Me Incorporates NCCN Hereditary Cancer Risk Testing Guidelines Into Patient-Facing App Oct 8, 2021 Invitae, Outcomes4Me Collaborate to Improve Breast Cancer Genetic Testing Access Apr 23, 2021 In Brief This Week: AstraZeneca, Amgen, Oncocyte, Rain Therapeutics Apr 5, 2021 Invitae Acquiring Genosity for $200M; Investment Group Provides Firm $1.15B in Senior Notes Feb 26, 2021 In Brief This Week: Kura Oncology, Innovent Biologics, Iaso Biotherapeutics, Invitae, Hologic Jan 14, 2021 Invitae, Pharma Firms Partner to Develop Standard MRD Panel for AML Clinical Trials Jan 13, 2021 JP Morgan Healthcare, Day 2: Eli Lilly, Pfizer, GlaxoSmithKline, Clovis Oncology, Invitae, and More Nov 23, 2020 FDA Accepts Invitae Premarket Approval Submission for Stratafide Companion Diagnostic Nov 17, 2020 Reinsurer SCOR Offering Cancer Genomic Testing as Benefit for Policyholders, Life Insurance Clients Premium Oct 30, 2020 Broad Genetic Testing Uncovers Additional Risk Variants in Cancer Patients, Study Finds Oct 14, 2020 Pfizer, Invitae Focus on Expanding Global BRCA1/2 Test Access Amid Treatment, Screening Barriers Premium Oct 8, 2020 Germline Genetic Testing After Tumor Sequencing Can Uncover Clinically Actionable Variants Oct 5, 2020 Invitae Completes Acquisition of ArcherDx Sep 8, 2020 Relaunched Canadian BRCA1/2 Screening Project Aims to ID High-Risk Carriers, Intervene Early Premium Sep 3, 2020 Invitae Launches Study to Explore Impact of Testing Guidelines on Prostate Cancer Patients' Outcomes Jun 22, 2020 Invitae, ArcherDx Ink $1.4B Merger to Advance Precision Oncology Offerings Load More Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week:Â Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
